{
    "clinical_study": {
        "@rank": "16",
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on April 09, 2020",
            "link_text": "Link to the current ClinicalTrials.gov record.",
            "url": "https://clinicaltrials.gov/show/NCT04306497"
        },
        "id_info": {
            "org_study_id": "JSZYJ202001",
            "nct_id": "NCT04306497"
        },
        "brief_title": "Clinical Trial on Regularity of TCM Syndrome and Differentiation Treatment of COVID-19.",
        "acronym": "CTOROTSADTOC",
        "official_title": "Clinical Trial on Regularity of TCM Syndrome and Differentiation Treatment of COVID-19 in Jiangsu Province",
        "sponsors": {
            "lead_sponsor": {
                "agency": "Jiangsu Famous Medical Technology Co., Ltd.",
                "agency_class": "Industry"
            }
        },
        "source": "Jiangsu Famous Medical Technology Co., Ltd.",
        "oversight_info": {
            "is_fda_regulated_drug": "No",
            "is_fda_regulated_device": "No"
        },
        "brief_summary": {
            "textblock": "Evaluation of the efficacy and safety of TCM differential treatment of COVID-19 in Jiangsu\n      Province based on a prospective multicenter cohort study."
        },
        "detailed_description": {
            "textblock": "In order to further observe the efficacy and safety of this project under natural\n      intervention. A prospective multicenter cohort study was designed, focusing on the common\n      type with the largest number of confirmed cases, to evaluate the intervention effect of this\n      project in relieving the disease and preventing disease progression, in order to provide more\n      sufficient clinical evidence for the further improvement and application of this project.\n\n      According to the actual situation of receiving treatment, according to whether or not exposed\n      to this study to observe the treatment of TCM, COVID-19 (common type) will be divided into\n      two cohorts: control group (western medicine cohort) and exposure group (integrated\n      traditional Chinese and western medicine cohort). The choice of treatment for patients is\n      entirely determined by clinicians according to the patient's condition, and patients are free\n      to choose after fully understanding different schemes). western medicine cohort:Routine\n      treatment + one or both of the following antiviral drugs.Cohort of integrated TCM and western\n      medicine: routine treatment + one or two of the following antiviral drugs + the following TCM\n      regimens.The sample size is tentatively set at 340."
        },
        "overall_status": "Recruiting",
        "start_date": {
            "@type": "Actual",
            "#text": "March 2, 2020"
        },
        "completion_date": {
            "@type": "Anticipated",
            "#text": "May 2020"
        },
        "primary_completion_date": {
            "@type": "Anticipated",
            "#text": "May 2020"
        },
        "study_type": "Observational",
        "has_expanded_access": "No",
        "study_design_info": {
            "observational_model": "Cohort",
            "time_perspective": "Prospective"
        },
        "primary_outcome": [
            {
                "measure": "The relief / disappearance rate of main symptoms",
                "time_frame": "9day",
                "description": "disappearance of fever, cough and shortness of breath/ the rate of complete relief /."
            },
            {
                "measure": "Chest CT absorption",
                "time_frame": "9day",
                "description": "with reference to the \"pneumonia chest X-ray absorption Evaluation scale\" developed by Renyi Yin et al, the final absorption judgment will be used to evaluate the chest CT absorption of patients with pneumonia, which is divided into four levels according to the degree of absorption: complete absorption, majority absorption, partial absorption and no absorption."
            }
        ],
        "secondary_outcome": [
            {
                "measure": "Virus antigen negative conversion rate",
                "time_frame": "9day",
                "description": "detection negative rat of nasopharyngeal swab, conjunctival sac secretion virus nucleic acid e"
            },
            {
                "measure": "Clinical effective time: the average effective time",
                "time_frame": "9day",
                "description": "the average time it takes for the clinical curative effect to reach the effective standard. Median response time: the average time it takes for 50% of patients to reach the effective standard."
            },
            {
                "measure": "The number of severe and critical conversion cases",
                "time_frame": "9day",
                "description": "the number of severe and critical cases occurred after the start of intervention."
            },
            {
                "measure": "Incidence of complications",
                "time_frame": "9day",
                "description": "defined as complications during isolation and hospitalization due to pneumonia infected by novel coronavirus, including bacterial infection, aggravation of underlying diseases, etc"
            },
            {
                "measure": "Traditional Chinese Medicine Syndrome Score",
                "time_frame": "9day",
                "description": "According to the Traditional Chinese Medicine symptom score scale, the change of symptom score before and after treatment was observed.The highest score was 92 points, and the lowest was 23 points. The higher the score, the more severe the symptoms."
            }
        ],
        "other_outcome": [
            {
                "measure": "CRP changes",
                "time_frame": "9day",
                "description": "Changes in c-reactive protein."
            },
            {
                "measure": "ESR changes",
                "time_frame": "9day",
                "description": "Changes in erythrocyte sedimentation rate."
            },
            {
                "measure": "PCTchanges",
                "time_frame": "9day",
                "description": "Changes in procalcitonin."
            },
            {
                "measure": "The index of T cell subsets changed",
                "time_frame": "9day",
                "description": "Changes of CD4+ and CD8+"
            }
        ],
        "number_of_groups": "2",
        "enrollment": {
            "@type": "Anticipated",
            "#text": "340"
        },
        "condition": "COVID-19",
        "arm_group": [
            {
                "arm_group_label": "Cohort of western medicine",
                "description": "Routine treatment\uff1a\n\u2460 support treatment:maintain water and electrolyte balance .\n\u2461oxygen therapy: give nasal catheters to inhale oxygen.\n\u2462 basic treatment of traditional Chinese and western medicine: antiviral drugs and proprietary Chinese medicines with similar composition or function to the observed scheme of differentiation and treatment of traditional Chinese medicine are not included in the scope of such drugs.\nAntiviral drugs \uff1aClinicians can judge according to the patient's condition according to the latest version of the diagnosis and treatment plan for COvID-19 issued by the General Office of the National Health Commission / the Office of the State Administration of traditional Chinese Medicine (currently the latest version is the sixth trial edition). Select any of the recommended antiviral drugs(for example:IFN-\u03b1\u3001lopinavir-ritonavir\u3001Ribavirin\u3001Chloroquine Phosphate\u3001Arbidol)or a combination of two antiviral drugs."
            },
            {
                "arm_group_label": "Cohort of integrated TCM and western medicine",
                "description": "routine treatment + Antiviral drugs + the following TCM regimens. 1.TCM regimens:\u2460 Early stage: Dampness trapped in exterior and interior. Recommended prescription: Huoxiang 15g, Suye15g, Cangzhu15g, Houpo10g, Qianhu15g, Chaihu15g, Huangqin10g, Qinghao20g, Xingren10g, JInyinhua15g, Lianqiao15g.\nTake decocted or granule, one dose a day.\n\u2461 Middle stage: Dampness-toxicity blocking lung Recommended prescription: Zhimahuang9g, Xingren10g, Sangbaipi30g, Tinglizi20g, Dongguazi20g, Fabanxia10g, Houpo10g, Suzi15g, Baijiezi10g, Gualoupi15g, Xuanfuhua9g, Xiangfu10g, Yujin10g, Taoren10g, Huangqi20g.\nTake decocted or granule, one dose a day."
            }
        ],
        "intervention": {
            "intervention_type": "Drug",
            "intervention_name": "TCM prescriptions",
            "description": "TCM prescriptions1:Take decocted or granule, one dose a day; TCM prescriptions2:Take decocted or granule, one dose a day.",
            "arm_group_label": [
                "Cohort of integrated TCM and western medicine",
                "Cohort of western medicine"
            ]
        },
        "eligibility": {
            "study_pop": {
                "textblock": "It conforms to the diagnostic criteria of confirmed cases of COVID-19."
            },
            "sampling_method": "Probability Sample",
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  It conforms to the diagnostic criteria of confirmed cases of COVID-19;\n\n          -  Age from 18-75, regardless gender.\n\n          -  The patient informed consent and sign the informed consent form (if the subject has no\n             capacity, limited capacity and limited expression of personal will, he or she should\n             obtain the consent of his guardian and sign the informed consent at the same time).\n\n        Exclusion Criteria:\n\n          -  Women during pregnancy or lactation;\n\n          -  Allergic constitution, such as those who have a history of allergy to two or more\n             drugs or food, or who are known to be allergic to drug ingredients observed in this\n             study.\n\n          -  Severe complications such as multiple organ failure and shock occurred.\n\n          -  Complicated with severe primary diseases such as heart, brain, liver, kidney and so\n             on.\n\n          -  Patients have mental illness.\n\n          -  Patients who participated in or is currently participating in other clinical trials\n             within the first month of this study."
            },
            "gender": "All",
            "minimum_age": "18 Years",
            "maximum_age": "75 Years",
            "healthy_volunteers": "No"
        },
        "overall_contact": {
            "last_name": "Haibo Cheng, phD",
            "phone": "13815857118",
            "email": "363994906@qq.com"
        },
        "overall_contact_backup": {
            "last_name": "Zhe Feng, phD",
            "phone": "13584046875",
            "email": "794200027@qq.com"
        },
        "location": {
            "facility": {
                "name": "Huai'an fourth people's Hospital",
                "address": {
                    "city": "Huaian",
                    "state": "Jiangsu",
                    "zip": "210029",
                    "country": "China"
                }
            },
            "status": "Recruiting",
            "contact": {
                "last_name": "Lei Cui, phD",
                "phone": "13951266803",
                "email": "houy@famousmed.net"
            }
        },
        "location_countries": {
            "country": "China"
        },
        "verification_date": "January 2020",
        "study_first_submitted": "March 1, 2020",
        "study_first_submitted_qc": "March 10, 2020",
        "study_first_posted": {
            "@type": "Actual",
            "#text": "March 13, 2020"
        },
        "last_update_submitted": "March 14, 2020",
        "last_update_submitted_qc": "March 14, 2020",
        "last_update_posted": {
            "@type": "Actual",
            "#text": "March 17, 2020"
        },
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        },
        "keyword": [
            "COVID-19",
            "Syndrome investigation",
            "differentiation treatment",
            "multicenter cohort study"
        ],
        "condition_browse": {
            "mesh_term": "Syndrome"
        },
        "patient_data": {
            "sharing_ipd": "Undecided",
            "ipd_description": "All researchers in this study"
        }
    }
}